Star Company to Boost Binhai’s Biomedical Development

A report from exploringtianjin on Aug. 31, 2021:

As one of the four-star strategic emerging industries in Binhai New Area in North China’s Tianjin Municipality, biomedical industry will achieve an annual income of 100 billion yuan ($15.44 billion), by 2025.

The new area has gathered together more than 1,500 biomedical companies, which have made scientific achievements in key areas, such as vaccines, recombinant proteins, stem cells, and high-end medical devices.

CanSinoBIO, one case in point, has, since establishment in the new area in 2009, experienced tremendous growth with 16 vaccines preventing 13 diseases, including approved vaccines for Ebola virus disease, COVID-19, and meningitis.

In March 2019, CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) and a year later, listed on Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company.

The company has in-licensed a number of new technologies and intellectual properties through collaborations with international research organizations and biotechnology companies.

CanSinoBIO collaborates through partnerships with world-class academic centers or start-up companies that develop innovative technologies, to prepare the portfolio of the next decades and ensure sustainable growth of the company.

It is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates.

In 2020, Binhai 's biomedical industry output value sat at 40.25 billion yuan, accounting for 64.2 percent of the city's total biomedical output.

By 2025, Binhai New Area in North China’s Tianjin Municipality will have been shaped into a highly innovative and internationally competitive drug development and drug manufacturing piloting zone, characterized by its comprehensive subdivisions and variety of complete medical products.

Tens of billions of yuan’s worth of well-designed industry clusters dedicated respectively to pharmaceutical, biotechnology, medical device, diagnostics and modern Chinese medicine will take shape and be formed in the area.

Smart technology applications have gradually been applied to facilitate the upgrading and modernization of production and manufacturing. The area has also seen an increase in international cooperation and roles.

Binhai is now luring international talents to further boost its biomedical industry.